1. Home
  2. MLYS vs DHC Comparison

MLYS vs DHC Comparison

Compare MLYS & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • DHC
  • Stock Information
  • Founded
  • MLYS 2019
  • DHC 1998
  • Country
  • MLYS United States
  • DHC United States
  • Employees
  • MLYS N/A
  • DHC N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • DHC Real Estate Investment Trusts
  • Sector
  • MLYS Health Care
  • DHC Real Estate
  • Exchange
  • MLYS Nasdaq
  • DHC Nasdaq
  • Market Cap
  • MLYS 634.6M
  • DHC 629.7M
  • IPO Year
  • MLYS 2023
  • DHC N/A
  • Fundamental
  • Price
  • MLYS $10.26
  • DHC $2.12
  • Analyst Decision
  • MLYS Strong Buy
  • DHC Hold
  • Analyst Count
  • MLYS 2
  • DHC 3
  • Target Price
  • MLYS $30.00
  • DHC $4.50
  • AVG Volume (30 Days)
  • MLYS 256.3K
  • DHC 898.3K
  • Earning Date
  • MLYS 03-20-2025
  • DHC 02-24-2025
  • Dividend Yield
  • MLYS N/A
  • DHC 1.89%
  • EPS Growth
  • MLYS N/A
  • DHC N/A
  • EPS
  • MLYS N/A
  • DHC N/A
  • Revenue
  • MLYS N/A
  • DHC $1,477,343,000.00
  • Revenue This Year
  • MLYS N/A
  • DHC N/A
  • Revenue Next Year
  • MLYS N/A
  • DHC $4.46
  • P/E Ratio
  • MLYS N/A
  • DHC N/A
  • Revenue Growth
  • MLYS N/A
  • DHC 6.62
  • 52 Week Low
  • MLYS $8.58
  • DHC $2.01
  • 52 Week High
  • MLYS $16.91
  • DHC $4.24
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 42.15
  • DHC 39.73
  • Support Level
  • MLYS $9.18
  • DHC $2.03
  • Resistance Level
  • MLYS $9.97
  • DHC $2.14
  • Average True Range (ATR)
  • MLYS 0.85
  • DHC 0.09
  • MACD
  • MLYS -0.09
  • DHC 0.02
  • Stochastic Oscillator
  • MLYS 34.80
  • DHC 29.73

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs.

Share on Social Networks: